BIBLIOS

Tipo
Artigos em Revista

Tipo de Documento
Artigo Completo

Título
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

Participantes na publicação
Miquéias Lopes-Pacheco (Author)
Dep. Química e Bioquímica
BioISI

Resumo
Cystic fibrosis (CF) is a lethal inherited disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which result in impairment of CFTR mRNA and protein expression, function, stability or a combination of these. Although CF leads to multifaceted clinical manifestations, the respiratory disorder represents the major cause of morbidity and mortality of these patients. The life expectancy of CF patients has substantially lengthened due to early diagnosis and improvements in symptomatic therapeutic regimens. Quality of life remains nevertheless limited, as these individuals are subjected to considerable clinical, psychosocial and economic burdens. Since the discovery of the CFTR gene in 1989, tremendous efforts have been made to develop therapies acting more upstream on the pathogenesis cascade, thereby overcoming the underlying dysfunctions caused by CFTR mutations. In this line, the advances in cell-based high-throughput screenings have been facilitating the fast-tracking of CFTR modulators. These modulator drugs have the ability to enhance or even restore the functional expression of specific CF-causing mutations, and they have been classified into five main groups depending on their effects on CFTR mutations: potentiators, correctors, stabilizers, read-through agents, and amplifiers. To date, four CFTR modulators have reached the market, and these pharmaceutical therapies are transforming patients' lives with short- and long-term improvements in clinical outcomes. Such breakthroughs have paved the way for the development of novel CFTR modulators, which are currently under experimental and clinical investigations. Furthermore, recent insights into the CFTR structure will be useful for the rational design of next-generation modulator drugs. This review aims to provide a summary of recent developments in CFTR-directed therapeutics. Barriers and future directions are also discussed in order to optimize treatment adherence, identify feasible and sustainable solutions for equitable access to these therapies, and continue to expand the pipeline of novel modulators that may result in effective precision medicine for all individuals with CF.


Instituição
FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA

Suporte
Frontiers in Pharmacology

Identificadores da Publicação
ISSN - 1663-9812

Editora
Frontiers Media SA



Identificadores do Documento
DOI - https://doi.org/10.3389/fphar.2019.01662
URL - http://dx.doi.org/10.3389/fphar.2019.01662
DOI - https://doi.org/10.3389/fphar.2019.01662

Identificadores de Qualidade
Web Of Science Q1 (2019) - 4.225 - PHARMACOLOGY & PHARMACY - SCIE
SCOPUS Q2 (2019) - 5 - Pharmacology
SCOPUS Q2 (2019) - 5 - Pharmacology (medical)
SCIMAGO Q1 (2019) - 1.228 - Pharmacology (medical)
SCIMAGO Q1 (2019) - 1.228 - Pharmacology

Keywords
CFTR mutations cell models clinical trials cystic fibrosis drug development high-throughput screening lung personalized medicine

Download